NCT03925714 Impact of P53 and SIRT1 in Type 2 Diabetes
| NCT ID | NCT03925714 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Sherief Abd-Elsalam |
| Condition | DM |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2019-04-01 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 90 participants in total. It began in 2019-04-01 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Investigating the impact of p53 and SIRT1 in the development of type 2 DM
Eligibility Criteria
Inclusion Criteria: * Prediabetic subjects. Exclusion Criteria: * Confirmed diabetes. * Hepatic or renal impairment.
Contact & Investigator
Eman SA Sawan, Msc
PRINCIPAL INVESTIGATOR
Tanta University - Faculty of Pharmacy
Frequently Asked Questions
Who can join the NCT03925714 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying DM. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03925714 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 90 participants.
Is NCT03925714 currently recruiting?
Yes, NCT03925714 is actively recruiting participants. Contact the research team at sheriefabdelsalam@yahoo.com for enrollment information.
Where is the NCT03925714 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT03925714 clinical trial?
NCT03925714 is sponsored by Sherief Abd-Elsalam. The principal investigator is Eman SA Sawan, Msc at Tanta University - Faculty of Pharmacy. The trial plans to enroll 90 participants.